Important Biotech Catalysts For September 7, 2022 - End Of The Day Summary

• The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Pfizer’s (NYSE:PFE) lead drug GBS6 or PF-06760805 for the prevention of invasive GBS disease due to the vaccine serotypes in newborns and young infants by active immunization of their mothers during pregnancy. Pfizer shares traded in a range of $45.39 to $46.21 on day volume of 15.31 million shares, closed regular trading session at $45.76.

• The European Commission has granted an orphan drug designation (ODD) to Viracta’s (NASDAQ:VIRX) lead drug combination nanatinostat and valganciclovir (Nana-val) for the treatment of peripheral T-cell lymphoma (PTCL). Viracta Therapeutics shares traded as high as 13.49 percent, in a range of $4.05 to $4.88 on day volume of 283.49 thousand shares, closed regular trading session at $4.81.